SNDX News and Press, Syndax Pharmaceuticals Inc. From 11/06/22

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Briggs Morrison - President and Head, R&D Keith Goldan -...

Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q3 GAAP EPS of -$0.58 beats by $0.07 . As of September 30, 2022, Syndax had cash, cash equivalents and short-term investments of $337.8M and 61.3M common shares and pre-funded warrants outstanding. Fo...

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update PR Newswire – Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1...

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias PR Newswire - 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) m...

Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022 PR Newswire WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical com...

Summary These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infer...

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Briggs Morrison - President and Head, R&D Keith Goldan...

Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q2 GAAP EPS of -$0.62. As of June 30, 2022, Syndax had cash, cash equivalents, short-term and long-term investments of $378.9 million For further details see: Syndax Pharmaceuticals GAAP EPS of -$0....

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation